Catalog No.: PC-21567Not For Human Use, Lab Use Only.
Catadegbrutinib (BGB-16673) is an orally available heterobifunctional BTK PROTAC degrader that binds to BTK and E3 ligase, degrades wildtype BTK and multiple mutant forms via ubiquitination.
Catadegbrutinib (BGB-16673) is an orally available heterobifunctional BTK PROTAC degrader that binds to BTK and E3 ligase, degrades wildtype BTK and multiple mutant forms via ubiquitination.
BGB-16673 exhibits high potency on clinically relevant BTK mutants resistant to covalent and non-covalent BTK inhibitors in cancer cells in vitro.
BGB-16673 drives complete tumor regression of lymphoma xenograft models expressing wildtype or BTK mutations resistant to covalent and non-covalent inhibitors.
BGB-16673 presents longer duration of response than BTK inhibitors in BTK wildtype and C481S mutant-expressing lymphoma xenograft models.
